Modified immunoglobulins for targeting amyloid deposits

Patent metadata

Field	Value
Publication number	US-12264195-B2
Application number	US-202418660162-A
Country	US
Kind code	B2
Filing date	May 9, 2024
Priority date	Nov 15, 2019
Publication date	Apr 1, 2025
Grant date	Apr 1, 2025

Abstract

Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.

First claim

We claim:

1. A method of treating a subject having systemic amyloidosis, comprising administering to the subject an effective amount of a modified immunoglobulin, comprising:
(i) an amyloid-reactive peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-14; and
(ii) an Ig antibody or functional fragment thereof that binds to human amyloid fibrils, wherein the Ig antibody or functional fragment thereof comprises a light chain comprising a light chain variable region (VL) and a heavy chain comprising a heavy chain variable region (VH), wherein:
a) the VL comprises a CDR-L1 comprising the amino acid sequence set forth in any one of SEQ ID NOs: 64-70, a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 21, and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:22, and the VH comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:17, a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:18, and a CDR-H3 comprising the amino acid sequence LDY;
b) the VL comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 20; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:21, and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:22, and the VH comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:17, a CDR-H2 comprising the amino acid sequence set forth in any one of SEQ ID NOs: 71-81; and a CDR-H3 comprising the amino acid sequence LDY; or
c) the VL comprises a CDR-L1 comprising the amino acid sequence set forth in any one of SEQ ID NOs: 64-70, a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 21, and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:22, and the VH comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:17, a CDR-H2 comprising the amino acid sequence set forth in any one of SEQ ID NOs: 71-81; and a CDR-H3 comprising the amino acid sequence LDY; and
wherein the modified immunoglobulin is a fusion protein comprising the Ig antibody or functional fragment thereof joined to the amyloid-reactive peptide.

2. The method of claim 1 , wherein the amyloid-reactive peptide comprises an amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.

3. The method of claim 1 , wherein the Ig antibody or functional fragment thereof comprises human framework sequences.

4. The method of claim 1 , wherein the Ig antibody or functional fragment thereof comprises a human Fc region.

5. The method of claim 1 , wherein the Ig antibody is humanized.

6. The method of claim 1 , wherein the VL comprises one or more amino acid residues selected from the group consisting of:
a. Tyr at position 36;
b. Leu at position 37;
c. Leu at position 46;
d. Leu at position 85; and
e. Phe at position 87,
wherein the amino acid positions are numbered according to the numbering system of Kabat.

7. The method of claim 1 , wherein the systemic amyloidosis is selected from the group consisting of AL, AH, Aβ2M, ATTR, transthyretin, AA, AApoAI, AApoAII, AGel, ALys, ALEct2, AFib, or ACys.

8. The method of claim 1 , wherein the subject is a human.

9. The method of claim 1 ,
wherein the VH comprises one or more amino acid residues selected from the group consisting of:
a. Val at position 37;
b. Leu at position 48;
c. Leu at position 67;
d. Ser at position 68;
e. Lys at position 71;
f. Ser at position 76;
g. Val at position 78;
h. Leu at position 79;
i. Phe at position 80;
j. Thr at position 89;
k. Val at position 93; and
l. Thr at position 94,
wherein the amino acid positions are numbered according to the numbering system of Kabat.

10. The method of claim 9 , wherein the VL comprises Leu at position 46 and Phe at position 87, and the VH comprises Leu at position 48, Ser at position 76, Val at position 78, Leu at position 79, Phe at position 80, and Thr at position 94.

11. The method of claim 10 , wherein the VL comprises the amino acid sequence set forth in SEQ ID NO:36 and the VH comprises the amino acid sequence set forth in SEQ ID NO:55.

12. The method of claim 11 , wherein the amyloid-reactive peptide comprises the amino acid sequence set forth in SEQ ID NO:2.

13. A method of identifying an amyloid deposit of a systemic amyloidosis in a subject, comprising:
administering a modified immunoglobulin to the subject, wherein the modified immunoglobulin comprises:
(i) an amyloid-reactive peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-14; and
(ii) an Ig antibody or functional fragment thereof that binds to human amyloid fibrils, wherein the Ig antibody or functional fragment thereof comprises a light chain comprising a light chain variable region (VL) and a heavy chain comprising a heavy chain variable region (VH), wherein:
a) the VL comprises a CDR-L1 comprising the amino acid sequence set forth in any one of SEQ ID NOs: 64-70, a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 21, and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:22, and the VH comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:17, a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:18, and a CDR-H3 comprising the amino acid sequence LDY;
b) the VL comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 20; a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:21, and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:22, and the VH comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:17, a CDR-H2 comprising the amino acid sequence set forth in any one of SEQ ID NOs: 71-81; and a CDR-H3 comprising the amino acid sequence LDY; or
c) the VL comprises a CDR-L1 comprising the amino acid sequence set forth in any one of SEQ ID NOs: 64-70, a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 21, and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:22, and the VH comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:17, a CDR-H2 comprising the amino acid sequence set forth in any one of SEQ ID NOs: 71-81; and a CDR-H3 comprising the amino acid sequence LDY; and
wherein the modified immunoglobulin is a fusion protein comprising the Ig antibody or functional fragment thereof joined to the amyloid-reactive peptide, and
wherein the modified immunoglobulin comprises a detectable label; and
detecting a signal from the modified immunoglobulin.

14. The method of claim 13 , wherein the VL comprises a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:64, a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:21, and a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:22, and the VH comprises a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:17, a CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:73, and a CDR-H3 comprising the amino acid sequence LDY.

15. The method of claim 13 , wherein the amyloid-reactive peptide comprises the amino acid sequence set forth in SEQ ID NO:2.

16. The method of claim 13 , wherein the Ig antibody or functional fragment thereof comprises human framework sequences.

17. The method of claim 13 , wherein the Ig antibody or functional fragment thereof comprises a human Fc region.

18. The method of claim 13 , wherein the VL comprises the amino acid sequence set forth in SEQ ID NO:36 and the VH comprises the amino acid sequence set

Assignees

• Attralus Inc
• Univ Tennessee Res Found

Inventors

• Wall Jonathan S
• Foster James S
• Guthrie Spencer

Classifications

• C12N15/85

  for animal cells · CPC title

• C07K2319/01

  containing a localisation/targetting motif · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title